Siegfried Holding AG operates in the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Siegfried Holding AG with three other
pharmaceutical manufacturers in Europe:
sales of 816.91 million Euros [US$890.84 million]
of which 46%
of UNITED KINGDOM
(£698.23 million [US$849.43 million]
of which 69%
was Product), and
based in SWEDEN
(8.94 billion Swedish Kronor [US$924.16 million]
of which 53%
was Healthcare Services).
Siegfried Holding AG reported sales of 833.51 million Swiss Francs (US$858.41 million)
December of 2019.
increase of 4.9%
versus 2018, when the company's sales were 794.30 million Swiss Francs.
Sales at Siegfried Holding AG have increased during each of the previous five years
(and since 2014, sales have increased a total of 164%).
Sales of Drug Substances saw an increase
7.2% in 2019, from
595.50 million Swiss Francs to 638.60 million Swiss Francs.
Not all segments of Siegfried Holding AG experienced an increase in sales in 2019:
sales of Drug Products fell 2.0% to 194.90 million Swiss Francs.